EDAP TMS S.A. (FOCL) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
EDAP TMS S.A. (FOCL) has outperformed Stereotaxis (STXS) over the past year, gaining 86.7% versus a loss of 68.9%. Over five years, FOCL leads with a -31.8% price change compared with -81.3% for STXS. EDAP TMS S.A. is the larger company by market cap ($194.8 million vs $111.2 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FOCL | STXS |
|---|---|---|
| Share price | $4.13 | $1.11 |
| Market cap | $194.77M | $111.22M |
| 1-day change | -1.55% | -1.77% |
| YTD return | +25.38% | -51.74% |
| 1-year return | +86.65% | -68.91% |
| 5-year return | -31.82% | -81.28% |
| EPS (TTM) | $-1.39 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.40 | $3.42 |
| 52-week low | $1.75 | $1.09 |
| Distance from 52-week high | -35.55% | -67.54% |
| Analyst consensus | buy | none |
| Avg. price target upside | +113.33% | +170.27% |
| Average volume | 114.80K | 808.41K |
| Shares outstanding | 47.22M | 100.20M |
| Employees | 289 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FOCL has outperformed STXS by 155.6 percentage points over the past year.
About EDAP TMS S.A.
FOCL stock →EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 289 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 131 employees
FOCL vs STXS FAQ
Which is bigger, EDAP TMS S.A. or Stereotaxis?
EDAP TMS S.A. (FOCL) is larger, with a market capitalization of $194.77M compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, FOCL or STXS?
FOCL returned +86.65% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are EDAP TMS S.A. and Stereotaxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.